Mirati Therapeutics Shares Move Higher, FDA Website Shows Approval Of Krazati (adagrasib)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216340
Why Mirati Therapeutics Shares Are Nosediving
Mirati Therapeutics Inc (NASDAQ: MRTX) shares are trading lower by 4.90% to $41.70 after Citigroup downgraded the stock from Buy to Neutral.
Citigroup Downgrades Mirati Therapeutics to Neutral, Lowers Price Target to $53
Citigroup analyst Yigal Nochomovitz downgrades Mirati Therapeutics (NASDAQ:MRTX) from Buy to Neutral and lowers the price target from $121 to $53.
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday’s Mid-Day Session
Gainers
My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.
Why Mirati Therapeutics Shares Are Getting Hammered Again Today
Mirati Therapeutics Inc (NASDAQ: MRTX) shares are trading lower by 12.18% to $43.55 during Thursday's session after multiple analysts downgraded their ratings on the stock and lowered their price targets.
What 10 Analyst Ratings Have To Say About Mirati Therapeutics
Over the past 3 months, 10 analysts have published their opinion on Mirati Therapeutics (NASDAQ:MRTX) stock. These analysts…
Chefs’ Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here are some big stocks recording losses in today’s session.
Lowe’s To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
Goldman Sachs raised Lowe’s Companies, Inc. (NYSE:LOW) price target from $241 to $246. . Goldman Sachs analyst Kate…
JP Morgan Downgrades Mirati Therapeutics to Neutral, Lowers Price Target to $65
JP Morgan analyst Eric Joseph downgrades Mirati Therapeutics (NASDAQ:MRTX) from Overweight to Neutral and lowers the price target from $94 to $65.
Why Mirati Therapeutics Stock Is Trading Sharply Lower Today
Mirati Therapeutics Inc (NASDAQ: MRTX) shares are trading lower by 29.32% to $50.55 on continued weakness after the company announced late-breaking results</